“…MiR-146-5p targets inflammatory mediators like COX2, IL-1β, KIT, NFKB1, TLR4, TRAF6 , and UHRF1 [ 78 ] and has been proposed as a predictor for asthma exacerbations in childhood asthma [ 79 , 80 ]. The anti-inflammatory miR-135b acts by targeting FOXN3 and RECK , an inhibitor of MMP2, and the known sEA pathogenesis factor MMP9 [ 81 , 82 , 83 ]. These anti-inflammatory actions might be the immunological counterbalance, and thus the defense mechanism of the lung against acute inflammation (likely Th17-mediated, as outlined above) during disease exacerbation.…”